Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).
Antonino Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Filippo Montemurro(Roche (Switzerland)), Rossana Berardi(Marche Polytechnic University), A. Caldara(Ospedale Santa Chiara), Stefania Gori(Ospedale Sacro Cuore Don Calabria), Nadia Naldi(University of Parma), Renata Todeschini(University of Parma), Giovanna Cavazzini(University of Padua), Federica Villa(Aziende Socio Sanitarie Territoriali di Lecco), R Porzio(Guglielmo da Saliceto Hospital), Michele Tognetto(University of Aberdeen), Antonio Frassoldati(University of Ferrara), Daniela Baldari(Tumour Institute of Tuscany), Alba A. Brandes(Istituto delle Scienze Neurologiche di Bologna), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Jennifer Foglietta(Ospedale Santa Maria), Daniela Rubino(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Alessio Schirone, Roberta Camisa(University of Parma), Benedetta Pellegrino(University of Parma)
Cited by 0
Related Papers
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors
|Proceedings of the National Academy of Sciences|2002|963
Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism
|Nature Medicine|2000|931